Limited sampling strategy of mycophenolic acid in adult kidney transplant recipients: Influence of the post-transplant period and the pharmacokinetic profile

Journal of Clinical Pharmacology

Volumn 53, Issue 9, 2013, Pages 925-933

  Chaabane, Amel ^a   Aouam, Karim ^a   Fredj, Nadia Ben ^a   Hammouda, Mouna ^b   Chadly, Zohra ^a   El May, Mezri ^b   Boughattas, Naceur ^a   Skhiri, Habib ^b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b University Hospital of Monastir   (Tunisia)

Author keywords

Kidney transplantation; Limited sampling strategy; Mycophenolic acid; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; MMF; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUNISIA;

KIDNEY TRANSPLANTATION; LIMITED SAMPLING STRATEGY; MYCOPHENOLIC ACID; THERAPEUTIC DRUG MONITORING;

ADOLESCENT; ADULT; AREA UNDER CURVE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TACROLIMUS; YOUNG ADULT;

EID: 84885047151     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.125     Document Type: Article

References (40)

1. Roth D, Colona J, Burke GW, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation. 1998;65:248-252. (Pubitemid 28099219)
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037.
3. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80:S244-S253. (Pubitemid 41552911)
4. Knight SR, Morris PJ. Does the evidence support the use of mycophenolatemofetil therapeutic drugmonitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675-1685.
5. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341-358.
6. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19. (Pubitemid 30083089)
7. Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672- 683. (Pubitemid 29011387)
8. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503. (Pubitemid 47566324)
9. Marcoux FS, Vandierdonck S, Premaud A, et al. Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit. 2011;33:285-294.
10. Mathew BS, Fleming DH, Annapandian VM, et al. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period. Ther Drug Monit. 2010;32:136-140.
11. Pawinski T, Durlik M, Szlaska I, et al. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first three months post transplant. J Clin Pharm Ther. 2006;31:27-34.
12. Miura M, Satoh S, Niioka T, et al. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit. 2008;30:52-59. (Pubitemid 351161099)
13. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504. (Pubitemid 34925784)
14. Miura M, Niioka T, Kato S, et al. Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. Ther Drug Monit. 2011;33:295-302.
15. Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57: 805-811. (Pubitemid 34143339)
16. Jirasiritham S, Sumethkul V, Mavichak V, et al. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc. 2004;36(7):2076-2078. (Pubitemid 39424331)
17. Miura M, Satoh S, Niioka T, et al. Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. Ther Drug Monit. 2009;31:467-474.
18. Filler G, Mai J. Limited sampling strategy for mycophenolic acid under the curve. Ther Drug Monit. 2000;22:169-173. (Pubitemid 30196820)
19. Toda T, Watanabe H, Kurosawa N, et al. Limited sampling strategy for estimating area under the concentration curve for mycophenolic acid in renal transplant recipients with coadministration of tacrolimus. Jpn J Pharm Health Care Sci. 2004;30:1-7.
20. Teshima D, Maiguma T, Kaji H, et al. Estimation of the area under the curve for mycophenolic acid in adult renal transplant patients with concomitant tacrolimus using a limited sampling strategy. J Clin Pharm Ther. 2008;33:159-163. (Pubitemid 351341407)
21. Barraclough KA, Isbel NM, Franklin ME, et al. Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients. Ther Drug Monit. 2010;32:723-733.
22. Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit. 2006;28:623-631. (Pubitemid 44564060)
23. Zicheng Y, Xianghui W, Peijun Z, et al. Evaluation of the practicability of limited sampling strategies for the estimation of mycophenolic acid exposure in Chinese adult renal recipients. Ther Drug Monit. 2007;29:600-606. (Pubitemid 47494058)
24. Muller H, Solari S, Zuniga C, et al. Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: an abbreviated sampling strategy. Transplant Proc. 2007;39:596-599. (Pubitemid 46574810)
25. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001;33:1052-1053. (Pubitemid 32237742)
26. Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000;22:549-554.
27. Vogl M, Weigel G, Seebacher G, et al. Evaluation of the EMIT mycophenolic acid assay from Dade Behring. Ther Drug Monit. 1999;21(6):638-643.
28. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1: 307-310. (Pubitemid 16134762)
30. Lee S, Shin M, Kim E, et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. Transplant Proc. 2010;42:793-796.
31. Picard N, Premaud A, Rousseau A, et al. A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol. 2006;62:477-484. (Pubitemid 44401531)
32. Marcos B, Bouzas L, TUTOR C. A limited sampling strategy for estimation of the area under the curve (0 to 8 hours) of mycophenolic acid administered three times daily to liver transplant recipients. Ups J Med Sci. 2011;116:47-51.
33. Kaczmarek I, Bigdeli AK, Vogeser M, et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit. 2008;30:419-427.
34. Ng J, Rogosheske J, Barker J, et al. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit. 2006;28:394-401. (Pubitemid 44314928)
35. Poulin E, Greanya ED, Partovi N, et al. Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens. Ther Drug Monit. 2011;33:50-55.
36. Crespo TMJ, Hermida J, Romero R, et al. Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus. J Clin Pharm Ther. 2009;34(5):531-537.
37. Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant. 2006;6: 121-128. (Pubitemid 43382210)
38. Nanni G, Pisanti F, Navarra P, et al. Lack of correlation between serum levels of mycophenolate mofetil and kidney transplant outcome in tacrolimus-based immunosupression. Transplant Proc. 2002;34(6):2085-2086. (Pubitemid 35299673)
39. Cho EK, Han DJ, Kim SC, et al. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol. 2004;44:743-750. (Pubitemid 38765936)
40. Premaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005;44:837-847. (Pubitemid 41126931)